Atricure Inc. Stock
Price
Target price
?
?
-0.530%
-0.2
-0.530%
€44.76
08:03 / Frankfurt
WKN: A0ES9W / Symbol: ATRC / Name: AtriCure / Stock / Healthcare Equipment & Supplies / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Atricure Inc. Stock
The price for the Atricure Inc. stock decreased slightly today. Compared to yesterday there is a change of -€0.200 (-0.530%).
With 6 Buy predictions and not the single Sell prediction the community is currently very high on Atricure Inc..
As a result the target price of 44 € shows a slightly positive potential of 18.28% compared to the current price of 37.2 € for Atricure Inc..
Pros and Cons of Atricure Inc. in the next few years
Pros
?
B****
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Cons
?
S********** s********
?
M***** P*******
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Atricure Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Atricure Inc. | -0.530% | 11.310% | 27.211% | -39.677% | 10.000% | -39.677% | -39.677% |
| Orthofix Medical Inc. | -2.290% | 0.575% | -11.616% | -24.569% | -32.171% | -50.843% | -73.485% |
| Lantheus Holdings Inc | -0.340% | -0.114% | -5.400% | 90.435% | 53.147% | 39.048% | - |
| Natera Inc | 0.070% | 16.963% | 12.427% | 96.788% | 36.853% | 423.495% | 215.322% |
Comments
AtriCure (ATRC) was given a new $50.00 price target by UBS Group AG. They now have a "buy" rating on the stock.
Show more
Ratings data for ATRC provided by MarketBeat
AtriCure (ATRC) was upgraded by Wall Street Zen from "buy" to "strong-buy".
Show more
Ratings data for ATRC provided by MarketBeat
AtriCure (ATRC) was upgraded by Freedom Capital to "strong-buy".
Show more
Ratings data for ATRC provided by MarketBeat
News
AtriCure Targets $1 Billion as Pain Management and AFib Trials Fuel Growth
Key Points
- Interested in AtriCure, Inc.? Here are five stocks we like better.
- AtriCure is targeting $1 billion in revenue by 2030, after reporting roughly 18% five-year compound growth, a 77%
Two AtriCure Directors Trimmed Shares After a Strong Quarter. Here's What Matters for Investors
Maggie Yuen, a director at AtriCure, Inc. (NASDAQ:ATRC), reported a sale of 3,500 shares of common stock on August 5, 2026, according to a recent SEC Form 4 filing.
Transaction value based on SEC
An AtriCure Director Sold $905,000 in Stock. Here's How to Read It
Karen Prange, a director of the company, sold 23,325 shares of common stock in AtriCure, Inc. (NASDAQ:ATRC) on August 5, according to an SEC Form 4 filing.
Transaction value based on SEC Form 4